- Effect of mepolizumab in airway remodeling in patients with late-onset severe asthma with an eosinophilic phenotype
- Severe Asthma Network Italy Definition of Clinical Remission in Severe Asthma: A Delphi Consensus
- Role of IL-5 in asthma and airway remodelling
- Mepolizumab-induced Changes in Nasal Methylome and Transcriptome to Predict Response in Asthma
- Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24-week treatment-free follow-up
- Mepolizumab Reduces Systemic Corticosteroid Use in Chronic Rhinosinusitis With Nasal Polyps
- Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): In-depth sinus surgery analysis
- Mepolizumab improves sense of smell in severe chronic rhinosinusitis with nasal polyps: SYNAPSE
- REDES Study: Mepolizumab Is Effective in Patients With Severe Asthma and Comorbid Nasal Polyps
- Respiratory comorbidities in severe asthma: focus on the pediatric age
- Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study
- Clinical Remission Achievement in Severe Asthma Following Mepolizumab Treatment: Results from the REALITI-A Study at 2 Years
- Targeting Asthma Remission as the Next Therapeutic Step Toward Improving Disease Control
- Clinical Remission Outcome in Patients with Severe Asthma with an Eosinophilic Phenotype (SA-EP) Receiving Mepolizumab: A Post-Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
- Evaluation of Clinical Remission in Best-Performing Severe Asthmatic Patients Treated for Three Years with Mepolizumab
- Interleukin-5 as a pleiotropic cytokine orchestrating airway type 2 inflammation: Effects on and beyond eosinophils
- Prospective REALITI-A Study: 2-Year Real-World Benefits of Mepolizumab in Severe Asthma
- Long-term safety of mepolizumab for up to ∼10 years in patients with severe asthma: open-label extension study
- Mepolizumab effectiveness for patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps in Italy (MEPOREAL): a real-life, multicentre, phase 4 trial